New to The Street's Esteemed Client Arrive AI Secures Another Key Patent for its Smart Mailbox-Anchored Autonomous Last-Mile Delivery Solutions Platform
This latest approval brings Arrive AI's total number of issued U.S. patents to eight, with six additional patents pending, and over 58 international filings across 22 countries. The proprietary technology strengthens Arrive AI's vision of reimagining last-mile delivery through a fusion of robotics, secure storage, and advanced environmental management systems.
The newly patented feature set includes:
On-demand heating and coolingBattery exchange and charging modulesExplosives and anthrax detectionUV and ozone-based sanitizationWeather condition sensorsPackage tracking and chain-of-custody systemsFacial recognition and two-way communication tools
Arrive AI's innovation stems from its early vision - one that predates similar concepts by industry giants. In fact, the foundational smart mailbox patent was filed four days before Amazon's comparable submission in 2014.
This milestone further positions Arrive AI at the forefront of autonomous delivery, providing critical infrastructure that bridges convenience, security, and compliance - particularly as the company enters high-demand markets such as healthcare, food service, e-commerce, and government.
Arrive AI is a long-term media partner of New to The Street, with regular broadcast features airing nationally across Fox Business Network and Bloomberg TV as sponsored programming. Its innovations have also been showcased across New to The Street's 2.5M+ YouTube subscriber base, providing expanded visibility to investors and stakeholders alike.
About Arrive AIArrive AI (NASDAQ: ARAI) is an autonomous logistics company specializing in smart mailbox technology and AI-powered last-mile delivery infrastructure. With a robust patent portfolio and strategic applications in healthcare, food, and retail, Arrive AI is shaping the future of how the world receives goods. Learn more at www.arrive.ai.
About New to The StreetNew to The Street is one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television platforms. Broadcasting weekly on Fox Business Network and Bloomberg TV, it also features companies on Times Square billboards, social media channels, and its 2.5 million+ subscriber YouTube channel, making it a global powerhouse in branded financial media.
Media Contact:Monica BrennanNew to The StreetMonica@NewToTheStreet.com
SOURCE: New to The Street
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Exclusive-Nvidia working on new AI chip for China that outperforms the H20, sources say
By Liam Mo and Fanny Potkin BEIJING/SINGAPORE (Reuters) -Nvidia is developing a new AI chip for China based on its latest Blackwell architecture that will be more powerful than the H20 model it is currently allowed to sell there, two people briefed on the matter said. U.S. President Donald Trump last week opened the door to the possibility of more advanced Nvidia chips being sold in China. But the sources noted U.S. regulatory approval is far from guaranteed amid deep-seated fears in Washington about giving China too much access to U.S. artificial intelligence technology. The new chip, tentatively known as the B30A, will use a single-die design that is likely to deliver half the raw computing power of the more sophisticated dual-die configuration in Nvidia's flagship B300 accelerator card, the sources said. A single-die design is when all the main parts of an integrated circuit are made on one continuous piece of silicon rather than split across multiple dies. The new chip would have high-bandwidth memory and Nvidia's NVLink technology for fast data transmission between processors, features that are also in the H20 - a chip based on the company's older Hopper architecture. The chip's specifications are not completely finalised but Nvidia hopes to deliver samples to Chinese clients for testing as early as next month, said the sources who were not authorised to speak to media and declined to be identified. Nvidia said in a statement: "We evaluate a variety of products for our roadmap, so that we can be prepared to compete to the extent that governments allow." "Everything we offer is with the full approval of the applicable authorities and designed solely for beneficial commercial use," it said. The U.S. Department of Commerce did not respond to a Reuters request for comment. FLASHPOINT The extent to which China, which generated 13% of Nvidia's revenue in the past financial year, can have access to cutting-edge AI chips is one of the biggest flashpoints in U.S.-Sino trade tensions. Nvidia only received permission in July to recommence sales of the H20. It was developed specifically for China after export restrictions were put in place in 2023, but company was abruptly ordered to stop sales in April. Trump said last week he might allow Nvidia to sell a scaled-down version of its next-generation chip in China after announcing an unprecedented deal that will see Nvidia and rival AMD give the U.S. government 15% of revenue from sales of some advanced chips in China. A new Nvidia chip for China might have "30% to 50% off", he suggested in an apparent reference to the chip's computing power, adding that the H20 was "obsolete". U.S. legislators, both Democratic and Republican, have worried that access to even scaled-down versions of flagship AI chips will impede U.S. efforts to maintain its lead in artificial intelligence. But Nvidia and others argue that it is important to retain Chinese interest in its chips - which work with Nvidia's software tools - so that developers do not completely switch over to offerings from rivals like Huawei. Huawei has made great strides in chip development, with its latest models said to be on par with Nvidia in some aspects like computing power, though analysts say it lags in key areas such as software ecosystem support and memory bandwidth capabilities. Complicating Nvidia's efforts to retain market share in China, Chinese state media have also in recent weeks alleged that the U.S firm's chips could pose security risks, and authorities have cautioned Chinese tech firms about purchasing the H20. Nvidia says its chips carry no backdoor risks. Nvidia is also preparing to start delivering a separate new China-specific chip based on its Blackwell architecture and designed primarily for AI inference tasks, according to two other people familiar with those plans. Reuters reported in May that this chip, currently dubbed the RTX6000D, will sell for less than the H20, reflecting weaker specifications and simpler manufacturing requirements. The chip is designed to fall under thresholds set by the U.S. government. It uses conventional GDDR memory and features memory bandwidth of 1,398 gigabytes per second, just below the 1.4 terabyte threshold established by restrictions introduced in April that led to the initial H20 ban. Nvidia is set to deliver small batches of RTX6000D to Chinese clients in September, said one of the people.
CNBC
7 minutes ago
- CNBC
CNBC Daily Open: OpenAI CEO, who sparked AI frenzy, worries about AI bubble
There's a bubble forming in the artificial intelligence industry, according to OpenAI CEO Sam Altman. "Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes. Is AI the most important thing to happen in a very long time? My opinion is also yes," Altman said. "I'm sure someone's gonna write some sensational headline about that. I wish you wouldn't, but that's fine," he added. (Apologies to Altman.) Altman's AI company is currently in talks to sell about $6 billion in stock that would value OpenAI at around $500 billion, CNBC confirmed Friday. In another conversation, Altman warned that the U.S. may be underestimating the progress that China is making in AI. Given the above premises, should investors be more cautious about OpenAI? Altman was not posed this question, but one wonders whether his opinion would also be "yes." Outside pure-play AI companies, the money is, likewise, still flowing. Intel is receiving a $2 billion injection of cash from Japan's SoftBank. It's a much-needed boost to the beleaguered U.S. chipmaker. Intel has fallen behind foreign rivals such as TSMC and Samsung in manufacturing semiconductors that serve as the brains for AI models. But going by Altman's views, the investment in Intel might not be a good bet by SoftBank CEO Masayoshi Son. Not everyone agrees with Altman, of course. Wedbush's Dan Ives told CNBC on Monday that there might be "some froth" in parts of the market, but "the actual impact over the medium and long term is actually being underestimated." And Ray Wang, research director for semiconductors, supply chain and emerging technology at Futurum Group, pointed out that the AI industry is not heterogeneous. There are market leaders, and then there are companies that are still developing. In the real world, bubbles delight because they reflect their surroundings in a play of light. But the bubble Altman described could be one doesn't show the face of its meeting paves the way for trilateral talks with Putin. At the White House meeting, the U.S. president also discussed security guarantees for Ukraine — which would reportedly involve a purchase around $90 billion of American weapons by Kyiv. Intel is getting a $2 billion investment from SoftBank. Both companies announced the development Monday, in which SoftBank will pay $23 per share for Intel's common stock. Shares of Intel jumped more than 5% in extended trading. The artificial intelligence market is in a bubble, says Sam Altman. Separately, the OpenAI CEO said he's "worried about China," and that the U.S. may be underestimating the latter's progress in artificial intelligence. U.S. stocks close mostly flat on Monday. The three major indexes made moves that were less than 0.1 percentage pointsin either direction as investors await key U.S. retail earnings. Asia-Pacific markets were mixed Tuesday. SoftBank shares fell as much as 5.7%. [PRO] Opportunities in one area of the European market. Investors have been pivoting away from the U.S. as multiple European indexes outperform those on Wall Street. But one pocket of Europe still remains overlooked, according to analysts. American money pours into Europe's soccer giants as club valuations soar European soccer is a bigger business than ever, with clubs in the continent's five top leagues raking in 20.4 billion euros ($23.7 billion) in revenue in the 2023-2024 season. American investors have been eyeing a piece of that pie. U.S. investors now own, fully or in part, the majority of soccer teams in England's Premier League. That now includes four of the traditional Big Six clubs, with Chelsea, Liverpool, Manchester United and Arsenal all attracting U.S. investment.
Business Upturn
37 minutes ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
